A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist

Molecular Pharmacology

Volumn 75, Issue 4, 2009, Pages 965-972

  Snider, Natasha T ^a   Nast, James A ^a   Tesmer, Laura A ^a   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 EPOXYEICOSATRIENOIC ACID ETHANOLAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLIC AMP; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 4F; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; FORSKOLIN; GAMMA INTERFERON; KETOCONAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL CULTURE; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DEGRADATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; EPOXIDATION; HUMAN; IMMUNOBLOTTING; MEMBRANE BINDING; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACIDS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; POLYUNSATURATED ALKAMIDES; RATS; RECEPTOR, CANNABINOID, CB2;

EID: 63849100862     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.053439     Document Type: Article

References (33)

1. Block ML, Zecca L, and Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57-69.
2. Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, and Kettenmann H (1992) An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res 31:616-621.
3. Bornheim LM, Kim KY, Chen B, and Correia MA (1995) Microsomal cytochrome P450-mediated liver and brain anandamide metabolism. Biochem Pharmacol 50: 677-686.
4. i determination [published erratum appears in: Drug Metab Dispos 36:203, 2008].
5. Drug Metab Dispos 35:2119-2126.
6. Cabral GA and Marciano-Cabral F (2005) Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 78:11921197.
7. Cabral GA, Raborn ES, Griffin L, Dennis J, and Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240-251.
8. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, and Cabral GA (2002) Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2:6982.
9. Chiamvimonvat N, Ho CM, Tsai HJ, and Hammock BD (2007) The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50:225-237.
10. Craib SJ, Ellington HC, Pertwee RG, and Ross RA (2001) A possible role of lipoxy-genase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 134:30-37.
11. Cravatt BF and Lichtman AH (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7:469-475.
12. Cui X, Kawashima H, Barclay TB, Peters JM, Gonzalez FJ, Morgan ET, and Strobel HW (2001) Molecular cloning and regulation of expression of two novel mouse CYP4F genes: expression in peroxisome proliferator-activated receptor α-deficient mice upon lipopolysaccharide and clofibrate challenges. J Pharmacol Exp Ther 296:542-550.
13. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613.
14. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
15. Di Marzo V (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7:438-455.
16. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, et al. (2006) The endocannabinoid anan-damide protects neurons during CNS inflammation by induction of MKP-1 inmicroglial cells. Neuron 49:67-79.
17. Funae Y, Kishimoto W, Cho T, Niwa T, and Hiroi T (2003) CYP2D in the brain. Drug Metab Pharmacokinet 18:337-349.
18. Gao HM and Hong JS (2008) Why neurodegenerative diseases are progressive:uncontrolled inflammation drives disease progression. Trends Immunol 29:357365.
19. Giang DK and Cravatt BF (1997) Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci U S A 94:2238-2242.
20. Howlett AC (2005) Cannabinoid receptor signaling. Handb Exp Pharmacol 168:5379.
21. Imig JD (2005) Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289:F496-F503.
22. Kaminski NE, Abood ME, Kessler FK, Martin BR, and Schatz AR (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42:736-742.
23. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, and Dittel BN (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95:437-445.
24. Matheny CJ, Ali RY, Yang X, and Pollack GM (2004) Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos 32:1008-1014.
25. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, and Compton DR (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
26. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, and Peterson PK (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49:211-219.
27. Shin JH, Engidawork E, Delabar JM, and Lubec G (2005) Identification and characterisation of soluble epoxide hydrolase in mouse brain by a robust protein biochemical method. Amino Acids 28:63-69.
28. Shoemaker JL, Seely KA, Reed RL, Crow JP, and Prather PL (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101: 87-98.
29. Siegle I, Fritz P, Eckhardt K, Zanger UM, and Eichelbaum M (2001) Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237-245.
30. Snider NT, Kornilov AM, Kent UM, and Hollenberg PF (2007) Anandamide metabolism by human liver and kidney microsomal cytochrome P450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. JPharmacol Exp Ther 321:590-597.
31. Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, and Hollenberg PF (2008) The Endocannabinoid Anandamide is a Substrate for the Human Polymorphic Cytochrome P450 2D6. J Pharmacol Exp Ther 327:538-545.
32. Sura P, Sura R, Enayetallah AE, and Grant DF (2008) Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem 56:551-559.
33. Woodward DF, Liang Y, and Krauss AH (2008) Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol 153:410-419.